A Phase 3 interventional study of L arginine and Placebo in Preeclampsia, sponsored by Hospital Civil Juan I. Menchaca. Completed at 1 site in Mexico. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-03-04.
Sponsored by Hospital Civil Juan I. Menchaca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pre-Eclampsia with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Pre-Eclampsia · Mexico.
Among the 11 studies in Pre-Eclampsia with a site in Mexico, this one is one of 2 that started in 2010, is the only one in phase 3, and was the 3rd registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →2 of the 11 studies in Pre-Eclampsia with a site in Mexico are open now. Recruiting first, the newest first:
Fundación Internacional René Mey · Sites in Mexico
Ages 18+ · Women only
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Mexico, Belgium, Colombia and 6 more countries
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2010.
This study's enrollment of 96 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 237 across the 6 interventional studies, 198 across the 5 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 8 most frequent:
Hospital Civil Juan I. Menchaca is the lead sponsor of 5 studies on the registry; none are open to participants now.
Hospital Civil Juan I. Menchaca has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Pre-Eclampsia with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04766866Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauSFlt1/PlGF and Planned Delivery to Prevent Preeclampsia At Term. | 2026-12-31 |
| NCT06953115Fundación Internacional René MeyVagal Stimulation Therapy and Preeclampsia | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Pre-Eclampsia with a site in Mexico, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized double-blind controled clinical trial to assess the efficacy and safety of L-arginine to prevent preeclampsia.
applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes
Two groups were formed. one received L arginine 3 grams orally at day from the 20th week of pregnancy. the other group received placebo.
Each three weeks were evaluated in search of high blood pressure and proteinuria.
The follow-up was until the end of pregnancy and two weeks after this
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same. dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Other: Placebo
were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
Dietary Supplement: L arginine
L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
calcined magnesia
efficacy of L arginine to prevent preeclampsia
number of patients with diagnosis of preeclampsia. the diagnostic was performed when they presented arterial blood pressure above 140/90 mm / Hg in the span of 6 hours and accompanied by proteinuria (\>300 milligrams in one sample) number of patients with high blood pression and proteinuria (ACOG criteria) The evaluations were performed every three weeks until week 31, then every two weeks until week 35 and weekly until pregnancy ended
Time frame: from time of randomization until the date of diagnostic of preeclampsia or two weeks after delivery wichever came first. approximalety 20 weeks.
perinatal outcome
number of patients with adverse perinatal outcome: APGAR scale \< 7 at five minutes, low weight for gestational age (\< 10 percentile) and CAPURRO scale \< 37 weeks also the need to enter the neonatal intensive care unit
Time frame: from time to delivery until two weeks after, approximalety 18 weeks
safety of L arginine
number of patients with adverse reactions and/or any alteration of blood test. participants are awarded a diary which recorded the symptoms that caused them any discomfort. If the discomfort was important it was reported via telephone with the treating physician. the paper was reviewed at each appointment. Blood tests such as blood count, liver function tests and kidney were performed every three weeks in search of alterations in the parameters considered normal by those tests (ACOG criteria)
Time frame: from time of randomization until birth approximalety 18 weeks
The record gives a start of Aug 2010, a primary completion of Aug 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine
Hospital Civil Juan I. Menchaca